Clinical Trial Update: A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating the safety of a 15-valent HPV vaccine in healthy Chinese adults aged 18-45. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia
• Genital Warts
• Hpv-related Carcinoma
• Human Papillomavirus Infection

Drugs mentioned

• 15-valent HPV vaccine (Human papillomavirus vaccine, 15-valent)

Snippet

Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Conditions: HPV Infection, HPV-Related Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING